Adirondack Trust Co. reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 7.7% during the third quarter, according to its most recent filing with the SEC. The fund owned 9,748 shares of the company’s stock after selling 813 shares during the quarter. Adirondack Trust Co.’s holdings in Merck & Co., Inc. were worth $821,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Titan Capital Management LLC CA purchased a new stake in Merck & Co., Inc. during the second quarter valued at about $25,000. LFA Lugano Financial Advisors SA lifted its holdings in Merck & Co., Inc. by 250.0% during the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after purchasing an additional 225 shares during the last quarter. JJJ Advisors Inc. purchased a new stake in Merck & Co., Inc. during the second quarter valued at about $27,000. Cumberland Partners Ltd purchased a new stake in Merck & Co., Inc. during the second quarter valued at about $40,000. Finally, Fusion Family Wealth LLC lifted its holdings in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after purchasing an additional 354 shares during the last quarter. 74.97% of the stock is currently owned by institutional investors.

In other news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total value of $546,873.43. Following the sale, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.27% of the company’s stock.

Several equities research analysts have commented on MRK shares. Mizuho reaffirmed a “buy” rating and set a $97.00 price objective on shares of Merck & Co., Inc. in a report on Sunday, September 8th. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $90.00 to $93.00 and gave the company an “overweight” rating in a report on Friday, June 14th. Bank of America set a $97.00 price objective on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, July 11th. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have issued a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average price target of $93.29.

Shares of Merck & Co., Inc. stock traded up $0.89 on Wednesday, reaching $84.18. The stock had a trading volume of 3,626,160 shares, compared to its average volume of 10,256,082. Merck & Co., Inc. has a 1 year low of $66.10 and a 1 year high of $87.35. The company has a market cap of $216.07 billion, a P/E ratio of 19.40, a price-to-earnings-growth ratio of 1.73 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The business’s 50 day moving average is $84.62 and its two-hundred day moving average is $82.22.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. During the same period in the prior year, the firm posted $1.06 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities analysts anticipate that Merck & Co., Inc. will post 4.92 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, October 7th. Stockholders of record on Monday, September 16th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date was Friday, September 13th. Merck & Co., Inc.’s payout ratio is 50.69%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.